Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of SYHX1901 in Healthy Chinese Subjects
NCT04880512Phase 1Unknown
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- May 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SYHX-1901 in plaque psoriasis, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (4 arms), sponsored by CSPC Ouyi Pharmaceutical. Primary endpoint: Safety and tolerability of SYHX1901 tablets. Status: unknown.
02
Drugs
SYHX-1901
03
Conditions
plaque psoriasisrheumatoid arthritis (RA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04880512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880512.